Gastrointestinal Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019-2026

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Gastrointestinal Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Gastrointestinal Drugs Market Overview

5. Market Dynamics
5.1. Drivers
5.1.1. Restraints
5.1.2. Opportunity
5.1.3. Trends
5.2. Porter’s Five Force Analysis
5.3. FDA Approved Biologics Products
5.4. Overview of Clinical Trials
5.5. Epidemiology of Gastrointestinal Disease: Global Scenario
5.6. Global prevalence of Inflammatory Bowel Disease in 2018

6. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Size (US$ Mn) Forecast By Drug Class
6.4.1. Acid Neutralizers
6.4.1.1. Antacids
6.4.1.2. H2 antagonists
6.4.1.3. Proton pump inhibitors
6.4.1.4. Helicobacter pylori eradication
6.4.2. Antidiarrheal and Laxatives
6.4.3. Antiemetic and Antinauseants
6.4.4. Anti-inflammatory drugs
6.4.5. Biologics
6.4.6. Others (Antispasmodic etc.)
6.5. Market Attractiveness By Drug Class

7. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market Size (US$ Mn) Forecast By Route of Administration
7.4.1. Oral
7.4.2. Intravenous
7.4.3. Rectal
7.5. Market Attractiveness By Route of Administration

8. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Disorder Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Key Trends
8.4. Market Size (US$ Mn) Forecast By Disorder Type
8.4.1. Gastroesophageal Reflux Disease
8.4.2. Inflammatory Bowel Disease
8.4.3. Irritable Bowel Syndrome
8.5. Market Attractiveness By Disorder Type

9. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Key Trends
9.4. Market Size (US$ Mn) Forecast By Distribution Channel
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Market Attractiveness By Distribution Channel

10. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Policies and Regulations
10.3. Market Size (US$ Mn) Forecast By Region
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. Asia Pacific
10.3.5. Middle East and Africa
10.4. Market Attractiveness By Country/Region

11. North America Gastrointestinal Drugs Market Analysis and Forecast
11.1. Key Findings
11.2. Policies and Regulations
11.3. Key Trends
11.4. Market Value Forecast By Country
11.4.1. US
11.4.2. Canada
11.5. Market Size (US$ Mn) Forecast By Drug Class
11.5.1. Acid Neutralizers
11.5.1.1. Antacids
11.5.1.2. H2 antagonists
11.5.1.3. Proton pump inhibitors
11.5.1.4. Helicobacter pylori eradication
11.5.2. Antidiarrheal and Laxatives
11.5.3. Antiemetic and Antinauseants
11.5.4. Anti-inflammatory drugs
11.5.5. Biologics
11.5.6. Others (Antispasmodic etc.)
11.6. Market Size (US$ Mn) Forecast By Route of Administration
11.6.1. Oral
11.6.2. Intravenous
11.6.3. Rectal
11.7. Market Size (US$ Mn) Forecast By Disorder Type
11.7.1. Gastroesophageal Reflux Disease
11.7.2. Inflammatory Bowel Disease
11.7.3. Irritable Bowel Syndrome
11.8. Market Size (US$ Mn) Forecast By Distribution Channel
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies
11.9. Market Attractiveness Analysis
11.9.1. By Country
11.9.2. By Drug Class
11.9.3. By Route of Administration
11.9.4. By Disorder Type
11.9.5. By Distribution Channel

12. Europe Gastrointestinal Drugs Market Analysis and Forecast
12.1. Key Findings
12.2. Policies and Regulations
12.3. Key Trends
12.4. Market Value Forecast By Country
12.4.1. Germany
12.4.2. France
12.4.3. U.K.
12.4.4. Italy
12.4.5. Russia
12.4.6. Spain
12.4.7. Rest of Europe
12.5. Market Size (US$ Mn) Forecast By Drug Class
12.5.1. Acid Neutralizers
12.5.1.1. Antacids
12.5.1.2. H2 antagonists
12.5.1.3. Proton pump inhibitors
12.5.1.4. Helicobacter pylori eradication
12.5.2. Antidiarrheal and Laxatives
12.5.3. Antiemetic and Antinauseants
12.5.4. Anti-inflammatory drugs
12.5.5. Biologics
12.5.6. Others (Antispasmodic etc.)
12.6. Market Size (US$ Mn) Forecast By Route of Administration
12.6.1. Oral
12.6.2. Intravenous
12.6.3. Rectal
12.7. Market Size (US$ Mn) Forecast By Disorder Type
12.7.1. Gastroesophageal Reflux Disease
12.7.2. Inflammatory Bowel Disease
12.7.3. Irritable Bowel Syndrome
12.8. Market Size (US$ Mn) Forecast By Distribution Channel
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Market Attractiveness Analysis
12.9.1. By Country
12.9.2. By Drug Class
12.9.3. By Route of Administration
12.9.4. By Disorder Type
12.9.5. By Distribution Channel

13. Asia Pacific Gastrointestinal Drugs Market Analysis and Forecast
13.1. Key Findings
13.2. Policies and Regulations
13.3. Key Trends
13.4. Market Value Forecast By Country
13.4.1. China
13.4.2. Japan
13.4.3. India
13.4.4. Australia & New Zealand
13.4.5. India
13.4.6. Rest of Asia Pacific
13.5. Market Size (US$ Mn) Forecast By Drug Class
13.5.1. Acid Neutralizers
13.5.1.1. Antacids
13.5.1.2. H2 antagonists
13.5.1.3. Proton pump inhibitors
13.5.1.4. Helicobacter pylori eradication
13.5.2. Antidiarrheal and Laxatives
13.5.3. Antiemetic and Antinauseants
13.5.4. Anti-inflammatory drugs
13.5.5. Biologics
13.5.6. Others (Antispasmodic etc.)
13.6. Market Size (US$ Mn) Forecast By Route of Administration
13.6.1. Oral
13.6.2. Intravenous
13.6.3. Rectal
13.7. Market Size (US$ Mn) Forecast By Disorder Type
13.7.1. Gastroesophageal Reflux Disease
13.7.2. Inflammatory Bowel Disease
13.7.3. Irritable Bowel Syndrome
13.8. Market Size (US$ Mn) Forecast By Distribution Channel
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Market Attractiveness Analysis
13.9.1. By Country
13.9.2. By Drug Class
13.9.3. By Route of Administration
13.9.4. By Disorder Type
13.9.5. By Distribution Channel

14. Latin America Gastrointestinal Drugs Market Analysis and Forecast
14.1. Key Findings
14.2. Policies and Regulations
14.3. Key Trends
14.4. Market Value Forecast By Country
14.4.1. Brazil
14.4.2. Mexico
14.4.3. Rest of Latin America
14.5. Market Size (US$ Mn) Forecast By Drug Class
14.5.1. Acid Neutralizers
14.5.1.1. Antacids
14.5.1.2. H2 antagonists
14.5.1.3. Proton pump inhibitors
14.5.1.4. Helicobacter pylori eradication
14.5.2. Antidiarrheal and Laxatives
14.5.3. Antiemetic and Antinauseants
14.5.4. Anti-inflammatory drugs
14.5.5. Biologics
14.5.6. Others (Antispasmodic etc.)
14.6. Market Size (US$ Mn) Forecast By Route of Administration
14.6.1. Oral
14.6.2. Intravenous
14.6.3. Rectal
14.7. Market Size (US$ Mn) Forecast By Disorder Type
14.7.1. Gastroesophageal Reflux Disease
14.7.2. Inflammatory Bowel Disease
14.7.3. Irritable Bowel Syndrome
14.8. Market Size (US$ Mn) Forecast By Distribution Channel
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Market Attractiveness Analysis
14.9.1. By Country
14.9.2. By Drug Class
14.9.3. By Route of Administration
14.9.4. By Disorder Type
14.9.5. By Distribution Channel

15. Middle East & Africa Gastrointestinal Drugs Market Analysis and Forecast
15.1. Key Findings
15.2. Policies and Regulations
15.3. Key Trends
15.4. Market Value Forecast By Country
15.4.1. GCC countries
15.4.2. South Africa
15.4.3. Rest of Middle East & Africa
15.5. Market Size (US$ Mn) Forecast By Drug Class
15.5.1. Acid Neutralizers
15.5.1.1. Antacids
15.5.1.2. H2 antagonists
15.5.1.3. Proton pump inhibitors
15.5.1.4. Helicobacter pylori eradication
15.5.2. Antidiarrheal and Laxatives
15.5.3. Antiemetic and Antinauseants
15.5.4. Anti-inflammatory drugs
15.5.5. Biologics
15.5.6. Others (Antispasmodic etc.)
15.6. Market Size (US$ Mn) Forecast By Route of Administration
15.6.1. Oral
15.6.2. Intravenous
15.6.3. Rectal
15.7. Market Size (US$ Mn) Forecast By Disorder Type
15.7.1. Gastroesophageal Reflux Disease
15.7.2. Inflammatory Bowel Disease
15.7.3. Irritable Bowel Syndrome
15.8. Market Size (US$ Mn) Forecast By Distribution Channel
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. Market Attractiveness Analysis
15.9.1. By Country
15.9.2. By Drug Class
15.9.3. By Route of Administration
15.9.4. By Disorder Type
15.9.5. By Distribution Channel

16. Competition Landscape
16.1. Market Player
16.2. Company Share Analysis (2016)
16.3. Company Profiles
16.3.1. Abbott Laboratories
16.3.1.1. Overview
16.3.1.2. Financials
16.3.1.3. Recent Developments
16.3.1.4. Strategy
16.3.2. Allergan Plc
16.3.2.1. Overview
16.3.2.2. Financials
16.3.2.3. Recent Developments
16.3.2.4. Strategy
16.3.3. AstraZeneca
16.3.3.1. Overview
16.3.3.2. Financials
16.3.3.3. Recent Developments
16.3.3.4. Strategy
16.3.4. Bayer AG
16.3.4.1. Overview
16.3.4.2. Financials
16.3.4.3. Recent Developments
16.3.4.4. Strategy
16.3.5. Boehringer Ingelheim GmbH
16.3.5.1. Overview
16.3.5.2. Financials
16.3.5.3. Recent Developments
16.3.5.4. Strategy
16.3.6. GlaxoSmithKline plc
16.3.6.1. Overview
16.3.6.2. Financials
16.3.6.3. Recent Developments
16.3.6.4. Strategy
16.3.7. Janssen Biotech, Inc.
16.3.7.1. Overview
16.3.7.2. Financials
16.3.7.3. Recent Developments
16.3.7.4. Strategy
16.3.8. Sanofi
16.3.8.1. Overview
16.3.8.2. Financials
16.3.8.3. Recent Developments
16.3.8.4. Strategy
16.3.9. Takeda Pharmaceutical
16.3.9.1. Overview
16.3.9.2. Financials
16.3.9.3. Recent Developments
16.3.9.4. Strategy
16.3.10. Valeant Pharmaceuticals, Inc.
16.3.10.1. Overview
16.3.10.2. Financials
16.3.10.3. Recent Developments
16.3.10.4. Strategy